Early View

Research letter

Transcutaneous CO2 measurement is not a reliable alternative to arterial blood gas sampling in the acute medical setting

Victoria Mummery, Eleanor Rogers, Vijay Padmanaban, Dionne Matthew, Thomas Woodcock, Susannah Bloch

Please cite this article as: Mummery V, Rogers E, Padmanaban V, et al. Transcutaneous CO2 measurement is not a reliable alternative to arterial blood gas sampling in the acute medical setting. Eur Respir J 2019; in press (https://doi.org/10.1183/13993003.01726-2018).

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2019
Title: Transcutaneous CO2 measurement is not a reliable alternative to arterial blood gas sampling in the acute medical setting.

Victoria Mummery¹, ², Eleanor Rogers¹, Vijay Padmanaban¹, Dionne Matthew², Thomas Woodcock², Susannah Bloch¹

1. Chest and Allergy Department, Imperial College Healthcare NHS Trust, London, UK
2. NIHR CLAHRC Northwest London, Imperial College London, Chelsea and Westminster Hospital, London, UK

• Corresponding author: Susannah Bloch, Chest and Allergy department, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London W2 1NY. Susannah.bloch@doctors.org.uk; 07977147483

Key Words : Transcutaneous CO2, Arterial Blood Gas (ABG)
Introduction

Measurement of the partial pressure of carbon dioxide in the arterial blood (pCO2) is essential in a variety of acute clinical settings and it is often necessary to monitor changes in pCO2 over time rather than just a one-off measurement. The current gold standard of measuring pCO2 is arterial blood gas (ABG) sampling, but the collection of arterial blood is invasive and associated with complications[1]. To avoid frequent arterial stabs, arterial lines are sometimes placed, but these result in the requirement for level 2 care and are associated with significant risks[2,3]. Transcutaneous measurement of CO2 (TcCO2) has been used in the field of sleep medicine and nocturnal monitoring of CO2 using the transcutaneous method is widely recognised. The technique is non-invasive, low-risk, requires minimal training and is well tolerated[4,5]. However, it is not known if TcCO2 can be used as a reliable measure of pCO2 in the acute setting and the evidence to date supporting its use has been contradictory and from small studies of selected patient groups[6-8], who were often medically stable[9]. Patients being treated with Non-Invasive Ventilation (NIV) are often those who require the most frequent ABG monitoring and the recent UK NCEPOD (National Confidential Enquiry in to Patient Outcome and Death) review of NIV care in the UK[10] highlights the need for careful and timely review of pCO2 in these patients. An arterial line can help avoid distress to the patient, but increased pressure on resources and level 2 beds means that this is not always available and patients may therefore have to be subjected to repeated arterial stabs. Therefore we hypothesised that TcCO2 would be reliable, easy to use and preferred by patients as a means of measuring CO2 in the acute unselected medical setting.

Methods

Medical patients admitted to hospital acutely unwell who required at least one ABG test were eligible to participate. Patients were identified and approached consecutively from acute medical admissions patient lists. Ethical approval for the study was obtained (REC 17/LO/1137: IRAS 228887). Written consent, demographic and clinical data were collected. Patients completed a questionnaire about their experience of both techniques.

CO2 measurement

The procedure for ABG sampling (both arterial stab and collection of blood from arterial lines) was carried out in the standard way either by the researcher or by the clinical team. ABGs were only taken at a time that was clinically indicated as determined by the clinical team. A Resmed SenTec monitor (SenTec AG, Ringstrasses 39, 4106 Therwil, Switzerland) was used to measure the TcCO2. Details of the standard set up and calibration of the machine can be found at www.sentec.ch.tv. In
Brief the technique involves the machine being used in its “spot check” mode and placement of an electrode sensor on the forehead of the patient. The sensor takes approximately 15 minutes to equilibrate before it will give a TcCO2 reading. The arterial blood was sampled at the point at which the machine delivered the equilibrated reading.

**Statistical Analysis**

Bland Altman analysis calculating the actual difference vs the mean was used to compare paired readings of pCO2 from arterial blood and the TcCO2 (Graphpad Prism 6); 95% limits of agreement were calculated and a pre-determined value of 0.25 kPa as an acceptable difference (Δ = ±0.25). The difference between the measurements was then correlated (Pearson’s correlation) with clinical parameters to determine any potentially influencing factors. The direction of change between two consecutive paired measurements within the same patient was compared between the two techniques of measuring CO2 (ie where more than one paired sample was taken from the same patient at different time points the question was asked ‘did the CO2 change in the same direction when measured by each technique’). Patient experience was analysed qualitatively.
Results

50 participants (23 male, median age 68 years, range 17-90 years) were recruited and consented to the study (72 screened, 5 patients did not require further ABG, 17 were unwilling or unable to consent). 45 patients completed the questionnaire; the 5 remaining were unable to partake in this element of the study due to their medical condition. Patients were admitted to hospital for a range of diagnoses – respiratory problems were most common (27/50,) followed by non-respiratory sepsis (7/50), then cardiovascular (5/50), the remaining 11 were admitted with other medical diagnosis (including neurological, diabetic and general medical issues). 74 paired samples (TcCO2 and pCO2) were collected; no one participant had more than 4 pairs of samples. The following clinical data were collected at the time of the CO2 measurements (expressed as median (range)): Temperature 36.7°C (35.7-38.4), oxygen saturations 93% (83-100); Heart rate 88 beats per minute (60-100), Mean Arterial blood pressure 86 mmHg (53-109). The arterial blood gas measurements showed a median pCO2 of 6.45 kPa (3.4-13.4) and the TcCO2 measurements 6.36 kPa (3.1-12.6) n=74 for both.

Bland Altman analysis suggested that the bias of the TcCO2 tended to be 0.16 (CI ± 1.54) kPa lower than the pCO2 with 95% limits of agreement -1.67 to 1.35 kPa (Figure 1, panel A). The difference between the 2 measurements was compared to the mean arterial blood pressure, heart rate, temperature and oxygen saturations – none of these parameters were found to affect how much the TcCO2 measurement differed from the pCO2 (data not shown). 24 samples were collected consecutively; however in only 54% of cases (13/24) did the CO2 change in the same direction when measured by the two techniques (Figure 1, panel B).

Patients overwhelmingly found the TcCO2 measurement more tolerable than the arterial stab. No patients reported any pain and the only other comments were three patients out of 45 reported a feeling of “warmth on the skin” during the TcCO2 measurement and one complained of slight heaviness where the probe was stuck to the skin. Arterial stabs were reported as painful and unpleasant (8 patients had arterial lines therefore did not comment on arterial stabs, 33 reported significant pain and the remaining 4 reported minor pain or a scratch.) Patients reported dreading arterial stabs where as 100% (45/45) said that they would have TcCO2 measurements in the future.
**Discussion**

TcCO2 is an attractive option for the measurement of CO2, it is non-invasive, allows the patient to be managed in a low acuity area and requires little skill to carry out. Other studies have variably shown that TcCO2 may\[6,7\] or may not\[8\] be a reliable alternative to the gold standard ABG pCO2. This larger real world study, recruiting unselected acutely unwell patients with a range of diagnoses, demonstrates that TcCO2 should not be used as an alternative to the ABG to monitor CO2 levels. The limitations to the study include the fact only a Resmed SenTec monitor was tested and only the forehead position was used for placement of the sensor, other devices or sensors in other positions may show other results. However in this study the limits of agreement for the two techniques of measuring TcCO2 were not only wide, but also lay significantly outside what may be an acceptable difference of ±0.25 kPa. This is in line with previous work\[11\]. Furthermore the TcCO2 could not be reliably used to suggest a trend or direction of change in CO2 level. This is disappointing both for staff and patients as our qualitative patient analysis clearly demonstrated that TcCO2 is a much more tolerable technique than ABG sampling. The study does not test whether or not either method of measuring pCO2 can be used to predict clinical outcomes or direct clinical decisions, the study question was limited only to if the two methods of measuring CO2 have comparable and clinically reliable results further research would be needed to answer this question. In conclusion, the results of this study suggest that TcCO2 measured by this method should not be used in the acute clinical setting as an alternative to the pCO2 measured by ABG sampling. Health economic pressures and patient experience considerations continue to call for more work to be done to find an alternative to the ABG.

**References**


5. Aarrestad S, Tollefson E, Kleiven AL, Qvarfort M, Janssens JP, Skjønsberg OH


Acknowledgements

This work was funded through a CLAHRC research driven QI project grant. Victoria Mummery was funded by this grant. Thomas Woodcock (CLAHRC) reviewed the statistical analysis. The work was supported by Resmed who loaned the SenTec machine. There are no conflicts of interest.

This article presents independent research in part funded by the National Institute for Health Research (NIHR) under the Collaboration for Leadership in Applied Health Research and Care (CLAHRC) programme for Northwest London.

The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Figure Legends

Figure 1:

Panel A: Bland-Altman plot to show the difference between CO2 measured by Transcutaneous CO2 monitoring (TcCO2) and Arterial Blood Gas analysis (ABG) vs mean of the two measurements. N= 74, dotted lines = 95% limits of agreement (-1.67 , 1.35), dashed lines = clinically acceptable difference ±0.25 kPa.

Panel B: Graph to show direction of change in CO2 between two consecutive measurements in the same patient when measured by Transcutaneous CO2 (TcCO2) vs Arterial Blood Gas analysis (ABG). N=24